LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (Nasdaq: AGIO) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Agios shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
Agios presented new data for its AG-348 and AG-519 molecules, used in treating pyruvate kinase deficiency, at the 2016 American Society of Hematology meeting. The Company reported that a case of Grade 2 thrombocytopenia, a reduction of platelets in blood cells, was found in a patient receiving AG-519 and that after a dose of 300 mg, a serious adverse event of drug-related cholestatic hepatitis was found in a bioavailability and food effect study. Following this disclosure, Agios stock dropped, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.